February 11, 2026 06:50 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bangladesh poll manifestos mirror India’s welfare schemes as BNP, Jamaat bet big on women, freebies | Drama ends: Pakistan makes U-turn on India boycott, to play T20 World Cup clash as per schedule | ‘Won’t allow any impediment in SIR’: Supreme Court pulls up Mamata govt over delay in sharing officers’ details | India-US trade deal: ‘Negotiations always two-way’, says Amul MD amid farmers’ concerns | Khamenei breaks 37-year-old ritual for first time amid escalating Iran-US tensions | India must push for energy independence amid global uncertainty: Vedanta chairman Anil Agarwal | Kanpur horror: Lamborghini driven by businessman’s son rams vehicles, injures six | ‘Namaste Trump beat Howdy Modi’: Congress slams PM Over India-US trade deal | Historic India-US trade pact: Tariffs cut, $500B market opportunity unlocked! | Big call from RBI: Repo rate stays at 5.25%, neutral stance continues

AstraZeneca to invest $50 billion in US, build largest factory in Virginia amid Trump tariff threats

| @indiablooms | Jul 22, 2025, at 08:40 pm

British pharmaceutical major AstraZeneca on Tuesday unveiled a $50 billion investment plan in the United States, which includes setting up a multi-billion-dollar manufacturing facility in Virginia—its largest single investment in manufacturing to date, according to media reports.

The move comes as the Trump administration escalates pressure on foreign pharmaceutical imports through proposed steep tariffs.

According to AFP, the company anticipates that half of its global revenue will come from the US by 2030, signalling a marked strategic pivot toward the American market.

“Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals,” AstraZeneca CEO Pascal Soriot said in a statement.

The announcement coincides with US President Donald Trump intensifying his stance on imposing tariffs on drug imports—an area previously spared in earlier rounds of trade levies.

A White House-commissioned investigation is currently underway, and new duties could go as high as 200%, according to hints from the administration.

“For decades Americans have been reliant on foreign supply of key pharmaceutical products,” US Commerce Secretary Howard Lutnick was quoted as saying by AFP.

He added that the proposed measures are designed to “end this structural weakness” in the domestic pharmaceutical supply chain.

AstraZeneca’s Virginia facility is set to be the centrepiece of its expanded footprint in the US and mirrors a broader industry trend.

Several other global drugmakers—who had largely escaped tariffs for the last three decades—are also beginning to move investment and manufacturing to American soil.

Back in April, AstraZeneca had already revealed plans to shift part of its European manufacturing base to the US, even before the current tariff momentum took shape.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm